Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine

Zahra Sahraei, Minoosh Shabani, Shervin Shokouhi, Ali Saffaei, Zahra Sahraei, Minoosh Shabani, Shervin Shokouhi, Ali Saffaei

No abstract available

Keywords: COVID-19; Chloroquine; Coronavirus; Hydroxychloroquine.

Figures

Fig. 1
Fig. 1
Chemical structure of (a) hydroxychloroquine and (b) chloroquine.

References

    1. Xu B., Kraemer M.U.G., Open COVID-19 Data Curation Group Open access epidemiological data from the COVID-19 outbreak. Lancet Infect Dis. 2020 Feb 19 doi: 10.1016/S1473-3099(20)30119-5. [Epub ahead of print]
    1. Colson P., Rolain J.M., Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents. 2020 doi: 10.1016/j.ijantimicag.2020.105923.
    1. Gao J., Tian Z., Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020 Feb 19 doi: 10.5582/bst.2020.01047. [Epub ahead of print]
    1. Rainsford K.D., Parke A.L., Clifford-Rashotte M., Kean W.F. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 2015;23:231–269. doi: 10.1007/s10787-015-0239-y.
    1. Savarino A., Boelaert J.R., Cassone A., Majori G., Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis. 2003;3:722–727. doi: 10.1016/s1473-3099(03)00806-5.
    1. Plantone D., Koudriavtseva T. Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review. Clin Drug Investig. 2018;38:653–671. doi: 10.1007/s40261-018-0656-y.
    1. Lim H.-S., Im J.-S., Cho J.-Y., Bae K.-S., Klein T.A., Yeom J.-S. Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. Antimicrob Agents Chemother. 2009;53:1468–1475. doi: 10.1128/AAC.00339-08.
    1. Jorge A.M., Melles R.B., Zhang Y., Lu N., Rai S.K., Young L.H. Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines. Arthritis Res Ther. 2018;20:133. doi: 10.1186/s13075-018-1634-8.
    1. Tan Y.W., Yam W.K., Sun J., Chu J.J.H. An evaluation of chloroquine as a broad-acting antiviral against hand, foot and mouth disease. Antiviral Res. 2018;149:143–149. doi: 10.1016/j.antiviral.2017.11.017.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa